Type 2 Diabetes Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)
Description
The type 2 diabetes market was valued at USD 35.00 Billion in 2024 , driven by the rising prevalence of type 2 diabetes across the 8 major markets. The market is expected to grow at a CAGR of 8.40% during the forecast period of 2025-2034, with the values likely to rise from USD 78.41 Billion by 2034 .
Type 2 Diabetes Market Overview
Type 2 diabetes refers to a chronic condition that affects the processing of blood sugar (glucose) in the body. People with type 2 diabetes often experience high blood sugar levels, a relative lack of insulin, and insulin resistance. The rising burden of type 2 diabetes is driving the demand for diabetes management solutions. Further, advancements in treatment options including the development of GLP-1 receptor agonists and insulin delivery technologies are poised to favor market growth. Moreover, the rise in public health campaigns and screening programs along with the growth in digital health solutions to advance diabetes care are anticipated to influence the market dynamics positively.
Type 2 Diabetes Market Growth Drivers
Increasing Prevalence of Type 2 Diabetes Drives Market Growth
The prevalence of diabetes is increasing rapidly across the globe, especially in low- and middle-income countries. Recent data suggests that 95% of people living with diabetes have type 2 diabetes, which can seriously damage the blood vessels and nerves in the body. It is estimated that 643 million people will have diabetes by 2030, which is further projected to increase to 783 million by 2045. Thus, the rising cases of type 2 diabetes are expected to contribute significantly to the market growth in the forecast period.
Type 2 Diabetes Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Rise in Strategic Mergers and Acquisitions to Affect the Market Landscape Significantly
Prominent market players are stepping forward to enhance their diabetes care portfolio propelled by the surge in the demand for diabetes medications. For instance, in March 2023, Sanofi announced the acquisition of Provention Bio, a United States-based biopharmaceutical company, in order to expand its diabetic care presence and reinforce its market position in the diabetes treatment space. Such strategic merger and acquisition events are expected to impact market growth.
Increased R&D Initiatives Poised to Elevate Type 2 Diabetes Market Value
The ongoing research and development directed at developing improved drugs with higher efficacy and fewer side effects is likely to aid market growth. For example, Fractyl Health, a Massachusetts-based biotech company, is working towards developing a one-time gene therapy intended to lower body weight as well as blood sugar levels. The drug is set to mimic a human hormone called GLP-1 that is released in the gut in response to eating. Such research initiatives are poised to favor market expansion in the coming years.
Surge in Regulatory Approvals to Augment the Type 2 Diabetes Market Demand
In August 2024 , Insulet Corporation, a medical device company specializing in insulin delivery systems, announced the U.S. Food and Drug Administration (FDA) approval of its patient-centric technology Omnipod 5 Automated Insulin Delivery System for the management of type 2 diabetes. The rise in regulatory approvals of innovative drugs and devices for type 2 diabetes is projected to amplify the market demand in the forecast period.
Growing Awareness Campaigns to Boost Type 2 Diabetes Market Size
To control and minimize the adverse effects of the disease, prominent organizations like the World Health Organization (WHO) have been initiating significant campaigns. WHO has launched a new initiative called BeatDiabetes in the Indian region, aimed at increasing awareness and promoting a healthy lifestyle. Such awareness campaigns are set to bolster the market demand for effective treatments.
Type 2 Diabetes Market Segmentation
Global Type 2 Diabetes Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Type
Market Segmentation Based on Drug Delivery Method is Anticipated to Witness Substantial Growth
The market breakup by drug delivery method includes oral, injections, pen devices, insulin devices, and others. Oral medications are most commonly used to manage type 2 diabetes, especially for patients who are in the early stages of the disease. Popular drugs like metformin and sulfonylureas are available in oral forms. Oral medications are easy to administer and are also a preferred option for patients who are hesitant about injections.
Type 2 Diabetes Market Analysis by Region
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States dominates the market share owing to a well-established infrastructure and the presence of major healthcare companies that are actively working to provide novel solutions. Further, significant funding to advance type 2 diabetes treatments is also expected the market growth in the region. For instance, in August 2023, the National Institutes of Health offered USD 3.5 million to conduct a large-scale clinical trial testing that can prove pivotal for new drug development.
Leading Players in the Type 2 Diabetes Market
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows
Novo Nordisk A/S
Danish multinational pharmaceutical Novo Nordisk is one of the leading players in the market, boasting production facilities in nine countries. The global healthcare company is actively focused on advancing treatment for type 2 diabetes from injections to tablets. Novo Nordisk has also demonstrated that a synthetic version of the glucagon-like peptide-1 (GLP-1) hormone, which lowers glucose levels in the blood, can be taken in the form of a tablet.
Sanofi SA
Headquartered in Paris, France, this multinational pharmaceutical and healthcare company has a prominent presence in the market. In April 2024 , Sanofi India launched Soliqua, a once-daily diabetes injectable drug in India at the cost of INR 1850 per pen.
Pfizer Inc.
Pfizer, based in New York, United States, significantly contributes to the development of the market through its extensive research capabilities and robust market presence. The company is engaged in the clinical development of its oral GLP-1-RA candidate danuglipron for the treatment of type 2 diabetes mellitus.
Merck & Co.
American multinational pharma Merck & Co. is a major market player and is known for its strong portfolio of prescription medicines, vaccines, and biologic therapies, among others. The company's 'See it. Slow it. Stop it.' campaign educates the public about the warning signs of type 2 diabetes and encourages people at risk to make simple lifestyle changes.
Other key players in the market include Boehringer Ingelheim International GmbH, Eli Lilly and Company, Abbott Laboratories, AstraZeneca plc, Bayer AG, and GSK plc., among others.
Key Questions Answered in the Type 2 Diabetes Market Report
Type 2 Diabetes Market Overview
Type 2 diabetes refers to a chronic condition that affects the processing of blood sugar (glucose) in the body. People with type 2 diabetes often experience high blood sugar levels, a relative lack of insulin, and insulin resistance. The rising burden of type 2 diabetes is driving the demand for diabetes management solutions. Further, advancements in treatment options including the development of GLP-1 receptor agonists and insulin delivery technologies are poised to favor market growth. Moreover, the rise in public health campaigns and screening programs along with the growth in digital health solutions to advance diabetes care are anticipated to influence the market dynamics positively.
Type 2 Diabetes Market Growth Drivers
Increasing Prevalence of Type 2 Diabetes Drives Market Growth
The prevalence of diabetes is increasing rapidly across the globe, especially in low- and middle-income countries. Recent data suggests that 95% of people living with diabetes have type 2 diabetes, which can seriously damage the blood vessels and nerves in the body. It is estimated that 643 million people will have diabetes by 2030, which is further projected to increase to 783 million by 2045. Thus, the rising cases of type 2 diabetes are expected to contribute significantly to the market growth in the forecast period.
Type 2 Diabetes Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Rise in Strategic Mergers and Acquisitions to Affect the Market Landscape Significantly
Prominent market players are stepping forward to enhance their diabetes care portfolio propelled by the surge in the demand for diabetes medications. For instance, in March 2023, Sanofi announced the acquisition of Provention Bio, a United States-based biopharmaceutical company, in order to expand its diabetic care presence and reinforce its market position in the diabetes treatment space. Such strategic merger and acquisition events are expected to impact market growth.
Increased R&D Initiatives Poised to Elevate Type 2 Diabetes Market Value
The ongoing research and development directed at developing improved drugs with higher efficacy and fewer side effects is likely to aid market growth. For example, Fractyl Health, a Massachusetts-based biotech company, is working towards developing a one-time gene therapy intended to lower body weight as well as blood sugar levels. The drug is set to mimic a human hormone called GLP-1 that is released in the gut in response to eating. Such research initiatives are poised to favor market expansion in the coming years.
Surge in Regulatory Approvals to Augment the Type 2 Diabetes Market Demand
In August 2024 , Insulet Corporation, a medical device company specializing in insulin delivery systems, announced the U.S. Food and Drug Administration (FDA) approval of its patient-centric technology Omnipod 5 Automated Insulin Delivery System for the management of type 2 diabetes. The rise in regulatory approvals of innovative drugs and devices for type 2 diabetes is projected to amplify the market demand in the forecast period.
Growing Awareness Campaigns to Boost Type 2 Diabetes Market Size
To control and minimize the adverse effects of the disease, prominent organizations like the World Health Organization (WHO) have been initiating significant campaigns. WHO has launched a new initiative called BeatDiabetes in the Indian region, aimed at increasing awareness and promoting a healthy lifestyle. Such awareness campaigns are set to bolster the market demand for effective treatments.
Type 2 Diabetes Market Segmentation
Global Type 2 Diabetes Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Type
- Oral
- Biguanides
- Meglitinides
- Thiazolidinediones
- Alpha-Glucosidase Inhibitors
- SGLT-2 Inhibitors
- Sulfonylureas
- Others
- Injectable
- Insulin
- GLP-1 Receptor Agonists
- Others
- Others
- Oral
- Injections
- Pen Devices
- Insulin Devices
- Others
- Hospitals and Clinics
- Retail Pharmacies
- Online Pharmacies
- Others
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Market Segmentation Based on Drug Delivery Method is Anticipated to Witness Substantial Growth
The market breakup by drug delivery method includes oral, injections, pen devices, insulin devices, and others. Oral medications are most commonly used to manage type 2 diabetes, especially for patients who are in the early stages of the disease. Popular drugs like metformin and sulfonylureas are available in oral forms. Oral medications are easy to administer and are also a preferred option for patients who are hesitant about injections.
Type 2 Diabetes Market Analysis by Region
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States dominates the market share owing to a well-established infrastructure and the presence of major healthcare companies that are actively working to provide novel solutions. Further, significant funding to advance type 2 diabetes treatments is also expected the market growth in the region. For instance, in August 2023, the National Institutes of Health offered USD 3.5 million to conduct a large-scale clinical trial testing that can prove pivotal for new drug development.
Leading Players in the Type 2 Diabetes Market
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows
Novo Nordisk A/S
Danish multinational pharmaceutical Novo Nordisk is one of the leading players in the market, boasting production facilities in nine countries. The global healthcare company is actively focused on advancing treatment for type 2 diabetes from injections to tablets. Novo Nordisk has also demonstrated that a synthetic version of the glucagon-like peptide-1 (GLP-1) hormone, which lowers glucose levels in the blood, can be taken in the form of a tablet.
Sanofi SA
Headquartered in Paris, France, this multinational pharmaceutical and healthcare company has a prominent presence in the market. In April 2024 , Sanofi India launched Soliqua, a once-daily diabetes injectable drug in India at the cost of INR 1850 per pen.
Pfizer Inc.
Pfizer, based in New York, United States, significantly contributes to the development of the market through its extensive research capabilities and robust market presence. The company is engaged in the clinical development of its oral GLP-1-RA candidate danuglipron for the treatment of type 2 diabetes mellitus.
Merck & Co.
American multinational pharma Merck & Co. is a major market player and is known for its strong portfolio of prescription medicines, vaccines, and biologic therapies, among others. The company's 'See it. Slow it. Stop it.' campaign educates the public about the warning signs of type 2 diabetes and encourages people at risk to make simple lifestyle changes.
Other key players in the market include Boehringer Ingelheim International GmbH, Eli Lilly and Company, Abbott Laboratories, AstraZeneca plc, Bayer AG, and GSK plc., among others.
Key Questions Answered in the Type 2 Diabetes Market Report
- What was the type 2 diabetes market value in 2024?
- What is the type 2 diabetes market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on drug type?
- What is the market breakup based on drug delivery methods?
- Who are the major end users in the market?
- What are the major factors aiding the type 2 diabetes market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How do the prevalence and incidence of type 2 diabetes affect the market landscape?
- What are the major type 2 diabetes market trends?
- How does the rise in the geriatric population impact the market size?
- Which drug type will dominate the market share?
- Which drug delivery method is expected to have a high market value in the coming years?
- Which end user is projected to contribute to the highest market growth?
- Who are the key players involved in the type 2 diabetes market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Type 2 Diabetes Market Overview: 8 Major Markets
- 3.1 Type 2 Diabetes Market Historical Value (2018-2024)
- 3.2 Type 2 Diabetes Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Type 2 Diabetes: Disease Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Therapy Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Therapy Success Rate
- 7 Type 2 Diabetes Market Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 United States
- 7.1.1.2 United Kingdom
- 7.1.1.3 EU4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 United States
- 7.1.2.2 United Kingdom
- 7.1.2.3 EU4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Seeking Rate, by Country
- 7.1.3.1 United States
- 7.1.3.2 United Kingdom
- 7.1.3.3 EU4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Type 2 Diabetes Market Landscape: 8 Major Markets*
- 8.1 Type 2 Diabetes Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Type 2 Diabetes Market: Product Landscape
- 8.2.1 Analysis by Drug Type
- 8.2.2 Analysis by Drug Delivery Method
- 9 Type 2 Diabetes Market Challenges and Unmet Needs
- 9.1 Therapy Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Type 2 Diabetes Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Type 2 Diabetes Market Segmentation: 8 Major Markets
- 12.1 Type 2 Diabetes Market (2018-2034) by Drug Type
- 12.1.1 Market Overview
- 12.1.2 Oral
- 12.1.2.1 Biguanides
- 12.1.2.2 Meglitinides
- 12.1.2.3 Thiazolidinediones
- 12.1.2.4 Alpha-Glucosidase Inhibitors
- 12.1.2.5 SGLT-2 Inhibitors
- 12.1.2.6 Sulfonylureas
- 12.1.2.7 Others
- 12.1.3 Injectable
- 12.1.3.1 Insulin
- 12.1.3.2 GLP-1 Receptor Agonists
- 12.1.3.3 Others
- 12.1.4 Others
- 12.2 Type 2 Diabetes Market (2018-2034) by Drug Delivery Method
- 12.2.1 Market Overview
- 12.2.2 Oral
- 12.2.3 Injections
- 12.2.4 Pen Devices
- 12.2.5 Others
- 12.3 Type 2 Diabetes Market (2018-2034) by End User
- 12.3.1 Market Overview
- 12.3.2 Hospitals and Clinics
- 12.3.3 Retail Pharmacies
- 12.3.4 Online Pharmacies
- 12.3.5 Others
- 12.4 Type 2 Diabetes Market (2018-2034) by Region
- 12.4.1 Market Overview
- 12.4.2 United States
- 12.4.3 EU-4 and the United Kingdom
- 12.4.3.1 Germany
- 12.4.3.2 France
- 12.4.3.3 Italy
- 12.4.3.4 Spain
- 12.4.3.5 United Kingdom
- 12.4.4 Japan
- 12.4.5 India
- 13 United States Type 2 Diabetes Market (218-2034)
- 13.1 United States Type 2 Diabetes Market Historical Value (2018-2024)
- 13.2 United States Type 2 Diabetes Market Forecast Value (2025-2034)
- 13.3 United States Type 2 Diabetes Market (2018-2034) by Drug Type
- 13.3.1 Market Overview
- 13.3.2 Oral
- 13.3.2.1 Biguanides
- 13.3.2.2 Meglitinides
- 13.3.2.3 Thiazolidinediones
- 13.3.2.4 Alpha-Glucosidase Inhibitors
- 13.3.2.5 SGLT-2 Inhibitors
- 13.3.2.6 Sulfonylureas
- 13.3.2.7 Others
- 13.3.3 Injectable
- 13.3.3.1 Insulin
- 13.3.3.2 GLP-1 Receptor Agonists
- 13.3.3.3 Others
- 13.3.4 Others
- 13.4 United States Type 2 Diabetes Market (2018-2034) by Drug Delivery Method
- 13.4.1 Market Overview
- 13.4.2 Oral
- 13.4.3 Injections
- 13.4.4 Pen Devices
- 13.4.5 Others
- 13.5 United States Type 2 Diabetes Market (2018-2034) by End User
- 13.5.1 Market Overview
- 13.5.2 Hospitals and Clinics
- 13.5.3 Retail Pharmacies
- 13.5.4 Online Pharmacies
- 13.5.5 Others
- 14 EU-4 and United Kingdom Type 2 Diabetes Market (218-2034)
- 14.1 EU-4 and United Kingdom Type 2 Diabetes Market Historical Value (2018-2024)
- 14.2 EU-4 and United Kingdom Type 2 Diabetes Market Forecast Value (2025-2034)
- 14.3 EU-4 and United Kingdom Type 2 Diabetes Market (2018-2034) by Drug Type
- 14.3.1 Market Overview
- 14.3.2 Oral
- 14.3.2.1 Biguanides
- 14.3.2.2 Meglitinides
- 14.3.2.3 Thiazolidinediones
- 14.3.2.4 Alpha-Glucosidase Inhibitors
- 14.3.2.5 SGLT-2 Inhibitors
- 14.3.2.6 Sulfonylureas
- 14.3.2.7 Others
- 14.3.3 Injectable
- 14.3.3.1 Insulin
- 14.3.3.2 GLP-1 Receptor Agonists
- 14.3.3.3 Others
- 14.3.4 Others
- 14.4 EU-4 and United Kingdom Type 2 Diabetes Market (2018-2034) by Drug Delivery Method
- 14.4.1 Market Overview
- 14.4.2 Oral
- 14.4.3 Injections
- 14.4.4 Pen Devices
- 14.4.5 Others
- 14.5 EU-4 and United Kingdom Type 2 Diabetes Market (2018-2034) by End User
- 14.5.1 Market Overview
- 14.5.2 Hospitals and Clinics
- 14.5.3 Retail Pharmacies
- 14.5.4 Online Pharmacies
- 14.5.5 Others
- 15 Japan Type 2 Diabetes Market (218-2034)
- 15.1 Japan Type 2 Diabetes Market Historical Value (2018-2024)
- 15.2 Japan Type 2 Diabetes Market Forecast Value (2025-2034)
- 15.3 Japan Type 2 Diabetes Market (2018-2034) by Drug Type
- 15.3.1 Market Overview
- 15.3.2 Oral
- 15.3.2.1 Biguanides
- 15.3.2.2 Meglitinides
- 15.3.2.3 Thiazolidinediones
- 15.3.2.4 Alpha-Glucosidase Inhibitors
- 15.3.2.5 SGLT-2 Inhibitors
- 15.3.2.6 Sulfonylureas
- 15.3.2.7 Others
- 15.3.3 Injectable
- 15.3.3.1 Insulin
- 15.3.3.2 GLP-1 Receptor Agonists
- 15.3.3.3 Others
- 15.3.4 Others
- 15.4 Japan Type 2 Diabetes Market (2018-2034) by Drug Delivery Method
- 15.4.1 Market Overview
- 15.4.2 Oral
- 15.4.3 Injections
- 15.4.4 Pen Devices
- 15.4.5 Others
- 15.5 Japan Type 2 Diabetes Market (2018-2034) by End User
- 15.5.1 Market Overview
- 15.5.2 Hospitals and Clinics
- 15.5.3 Retail Pharmacies
- 15.5.4 Online Pharmacies
- 15.5.5 Others
- 16 India Type 2 Diabetes Market (218-2034)
- 16.1 India Type 2 Diabetes Market Historical Value (2018-2024)
- 16.2 India Type 2 Diabetes Market Forecast Value (2025-2034)
- 16.3 India Type 2 Diabetes Market (2018-2034) by Drug Type
- 16.3.1 Market Overview
- 16.3.2 Oral
- 16.3.2.1 Biguanides
- 16.3.2.2 Meglitinides
- 16.3.2.3 Thiazolidinediones
- 16.3.2.4 Alpha-Glucosidase Inhibitors
- 16.3.2.5 SGLT-2 Inhibitors
- 16.3.2.6 Sulfonylureas
- 16.3.2.7 Others
- 16.3.3 Injectable
- 16.3.3.1 Insulin
- 16.3.3.2 GLP-1 Receptor Agonists
- 16.3.3.3 Others
- 16.3.4 Others
- 16.4 India Type 2 Diabetes Market (2018-2034) by Drug Delivery Method
- 16.4.1 Market Overview
- 16.4.2 Oral
- 16.4.3 Injections
- 16.4.4 Pen Devices
- 16.4.5 Others
- 16.5 India Type 2 Diabetes Market (2018-2034) by End User
- 16.5.1 Market Overview
- 16.5.2 Hospitals and Clinics
- 16.5.3 Retail Pharmacies
- 16.5.4 Online Pharmacies
- 16.5.5 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 INDIA CDSCO
- 17.5 JAPAN PMDA
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 18.7 Analysis by Key Players
- 19 Clinical Trial Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grant Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Product
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Drug Type of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Type of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share by Top 5 Companies
- 23.2 Novo Nordisk A/S
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Company News and Developments
- 23.2.5 Certifications
- 23.3 Sanofi SA
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Company News and Developments
- 23.3.5 Certifications
- 23.4 Pfizer Inc.
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Company News and Developments
- 23.4.5 Certifications
- 23.5 Merck & Co.
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Company News and Developments
- 23.5.5 Certifications
- 23.6 Boehringer Ingelheim International GmbH
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Company News and Developments
- 23.6.5 Certifications
- 23.7 Eli Lilly and Company
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Company News and Developments
- 23.7.5 Certifications
- 23.8 Abbott Laboratories
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Company News and Developments
- 23.8.5 Certifications
- 23.9 AstraZeneca plc
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Company News and Developments
- 23.9.5 Certifications
- 23.10 Bayer AG
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Company News and Developments
- 23.10.5 Certifications
- 23.11 GSK plc
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Company News and Developments
- 23.11.5 Certifications
- 24 Type 2 Diabetes Market – Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
